Format
Sort by

Send to

Choose Destination

Links from Books

Items: 12

1.

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.

Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ.

Br J Cancer. 2009 May 5;100(9):1385-92. doi: 10.1038/sj.bjc.6605017. Review.

2.

TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1.

Wilkins-Port CE, Ye Q, Mazurkiewicz JE, Higgins PJ.

Cancer Res. 2009 May 1;69(9):4081-91. doi: 10.1158/0008-5472.CAN-09-0043.

3.

Tumour necrosis factor and cancer.

Balkwill F.

Nat Rev Cancer. 2009 May;9(5):361-71. doi: 10.1038/nrc2628. Review.

PMID:
19343034
4.

Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines.

Wu WK, Tse TT, Sung JJ, Li ZJ, Yu L, Cho CH.

Anticancer Res. 2009 Jan;29(1):229-34.

5.

SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF.

Levashova Z, Backer MV, Horng G, Felsher D, Backer JM, Blankenberg FG.

Bioconjug Chem. 2009 Apr;20(4):742-9. doi: 10.1021/bc800443w.

PMID:
19320434
6.

EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.

Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA Jr, Hirsch FR.

J Thorac Oncol. 2009 Mar;4(3):318-25. doi: 10.1097/JTO.0b013e31819667a3.

7.

Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m.

Levashova Z, Backer M, Backer JM, Blankenberg FG.

Bioconjug Chem. 2008 May;19(5):1049-54. doi: 10.1021/bc7004818.

PMID:
18407683
8.

The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB.

Clin Cancer Res. 2007 Mar 15;13(6):1911-25.

9.

Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes.

Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FG, Backer JM.

Nat Med. 2007 Apr;13(4):504-9.

PMID:
17351626
10.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA.

J Clin Oncol. 2005 Nov 1;23(31):8081-92.

PMID:
16204011
11.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL.

J Clin Oncol. 2005 Apr 10;23(11):2445-59. Review. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281.

PMID:
15753456
12.

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB.

J Clin Oncol. 2005 Mar 20;23(9):1803-10.

PMID:
15677699
Items per page

Supplemental Content

Support Center